Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer.
Date
2022-10-18Author
Fendler, A
Shepherd, STC
Au, L
Wu, M
Harvey, R
Wilkinson, KA
Schmitt, AM
Tippu, Z
Shum, B
Farag, S
Rogiers, A
Carlyle, E
Edmonds, K
Del Rosario, L
Lingard, K
Mangwende, M
Holt, L
Ahmod, H
Korteweg, J
Foley, T
Barber, T
Emslie-Henry, A
Caulfield-Lynch, N
Byrne, F
Deng, D
Kjaer, S
Song, O-R
Queval, CJ
Kavanagh, C
Wall, EC
Carr, EJ
Caidan, S
Gavrielides, M
MacRae, JI
Kelly, G
Peat, K
Kelly, D
Murra, A
Kelly, K
O'Flaherty, M
Shea, RL
Gardner, G
Murray, D
Popat, S
Yousaf, N
Jhanji, S
Tatham, K
Cunningham, D
Van As, N
Young, K
Furness, AJS
Pickering, L
Beale, R
Swanton, C
Gandhi, S
Gamblin, S
Bauer, DLV
Kassiotis, G
Howell, M
Nicholson, E
Walker, S
Wilkinson, RJ
Larkin, J
Turajlic, S
Type
Journal Article
Metadata
Show full item recordAbstract
Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886), we report immune responses in 80 patients with blood cancer who received a fourth dose of BNT162b2. We measured neutralizing antibody titers (NAbTs) using a live virus microneutralization assay against wild-type (WT), Delta, and Omicron BA.1 and BA.2 and T cell responses against WT and Omicron BA.1 using an activation-induced marker (AIM) assay. The proportion of patients with detectable NAb titers and T cell responses after the fourth vaccine dose increased compared with that after the third vaccine dose. Patients who received B cell-depleting therapies within the 12 months before vaccination have the greatest risk of not having detectable NAbT. In addition, we report immune responses in 57 patients with breakthrough infections after vaccination.
Collections
Subject
COVID-19
SARS-CoV-2
T cells
blood cancer
neutralizing antibodies
variants of concern
Humans
Antibodies, Neutralizing
Antibodies, Viral
BNT162 Vaccine
Clinical Studies as Topic
COVID-19
COVID-19 Vaccines
Immunity
Neoplasms
SARS-CoV-2
Research team
Melanoma & Kidney Cancer
Medicine (RMH)
Skin Unit
Language
eng
Date accepted
2022-09-21
License start date
2022-10-18
Citation
Cell Reports Medicine, 2022, 3 (10), pp. 100781 -
Publisher
CELL PRESS